Literature DB >> 2307325

Effectiveness of chelation therapy with time after acute uranium intoxication.

J L Domingo1, A Ortega, J M Llobet, J Corbella.   

Abstract

The effect of increasing the time interval between acute uranium exposure and chelation therapy was studied in male Swiss mice. Gallic acid, 4,5-dihydroxy-1,3- benzenedisulfonic acid (Tiron), diethylenetriaminepentaacetic acid (DTPA), and 5-aminosalicylic acid (5-AS) were administered ip at 0, 0.25, 1, 4, and 24 hr after sc injection of 10 mg/kg of uranyl acetate dihydrate. Chelating agents were given at doses equal to one-fourth of their respective LD50 values. Daily elimination of uranium into urine and feces was determined for 4 days after which time the mice were killed, and the concentration of uranium was measured in kidney, spleen, and bone. The excretion of uranium was especially rapid in the first 24 hr. Treatment with Tiron or gallic acid at 0, 0.25, or 1 hr after uranium exposure significantly increased the total excretion of the metal. In kidney and bone, only administration of Tiron at 0, 0.25, or 1 hr after uranium injection, or gallic acid at 1 hr after uranium exposure significantly reduced tissue uranium concentrations. Treatment at later times (4 to 24 hr) did not increase the total excretion of the metal and did not decrease the tissue uranium concentrations 4 days after uranyl acetate administration. The results show that the length of time before initiating chelation therapy for acute uranium intoxication greatly influences the effectiveness of this therapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2307325     DOI: 10.1016/0272-0590(90)90234-b

Source DB:  PubMed          Journal:  Fundam Appl Toxicol        ISSN: 0272-0590


  3 in total

1.  Desferrithiocin analogue uranium decorporation agents.

Authors:  Raymond J Bergeron; Jan Wiegand; Shailendra Singh
Journal:  Int J Radiat Biol       Date:  2009-04       Impact factor: 2.694

2.  Uranium-Toxicity and Uranium-Induced Osteosarcoma Using A New Regimen and Surgery : A First-Time Experience.

Authors:  Tejbir Singh Pannu; Karamjit Singh Gill
Journal:  J Clin Diagn Res       Date:  2015-06-01

3.  A 3,2-Hydroxypyridinone-based Decorporation Agent that Removes Uranium from Bones In Vivo.

Authors:  Xiaomei Wang; Xing Dai; Cen Shi; Jianmei Wan; Mark A Silver; Linjuan Zhang; Lanhua Chen; Xuan Yi; Bizheng Chen; Duo Zhang; Kai Yang; Juan Diwu; Jianqiang Wang; Yujie Xu; Ruhong Zhou; Zhifang Chai; Shuao Wang
Journal:  Nat Commun       Date:  2019-06-25       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.